Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Hits Milestone in Multiple Sclerosis microRNA Biomarker Partnership


Regulus Therapeutics this week announced that it has received a milestone payment from Biogen Idec as part of the companies' ongoing partnership to identify microRNA biomarkers for multiple sclerosis.

In 2012, the companies signed a deal under which Regulus is using its proprietary miRNA extraction and analysis technologies to identify which of these small, non-coding RNAs could be used to develop a blood-based test to help diagnose MS patients, as well as to guide their treatment and monitor disease progression and relapse.

Regulus said that it has thus far profiled over 400 serum samples from MS patients and compared them against samples from healthy volunteers. Based on the progress made, Regulus has received an undisclosed milestone payment.

Under the terms of the companies deal, Regulus may receive $250,000 for identifying an miRNA biomarker; $500,000 for validation of the biomarker in a second independent sample set; and $500,000 upon "refinement of the microRNA biomarker signature from a longitudinal study of patients samples on MS therapy," according to a filing with the US Securities and Exchange Commission.

Regulus said that the companies are now conducting additional validation work on miRNA biomarker signatures on patients with relapse-remitting MS.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.